Plain-English translation of NCT06454448 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new drug called adebrelimab combined with three chemotherapy medications (decitabine, albumin-bound paclitaxel, and gemcitabine) to treat pancreatic cancer that has spread to other parts of the body. The medication works by helping your immune system recognize and attack cancer cells more effectively. Researchers believe this combination approach may work better than chemotherapy alone for people newly diagnosed with advanced pancreatic cancer.
Pancreatic cancer is very aggressive and hard to treat, and current treatments don't help enough patients. This medication is designed to work alongside chemotherapy by 'waking up' your immune system and helping it fight the cancer better, which researchers hope will improve survival and quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive four medications given through an IV (intravenous line) on a repeating 28-day schedule. Three of the chemotherapy drugs are given on days 1, 8, and 15 of each cycle, while the new medication (adebrelimab) is given on day 15. You would continue this treatment for as long as it is helping and you are tolerating it well. Throughout the trial, you would have regular blood tests and scans to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China